Project Grant HT94252311000
Award Date
8/31/23
Completion Date
8/29/25
Dollars Obligated
$577K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
The U.S. Department of Defense's Defense Health Agency awarded a $1,498,368 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to elucidate molecular mechanisms of tumor-immune dynamics and evolution in response to radiation in order to optimize treatment of high- and very high-risk prostate cancer. The award period runs from August 1, 2024 to July 31, 2027. As a...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), has been awarded a $1,000,236.00 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant, effective April 1, 2024 through March 31, 2028, will fund research to "UNLOCK THE CTDNA MUTATIONAL PATTERNS FOR EARLY CANCER DETECTION AND NONINVASIVE BIOMARKERS." As a leading academic medical center and research...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), received a $1,865,846 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on July 1, 2024. The funding will support the project "TARGETING NEUROIMMUNE AND EPITHELIAL SIGNALING FOR ECZEMA TREATMENT" through June 30, 2028. MGH, a leading academic medical center and research institution, will conduct biomedical research,...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,234,505.00 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research aimed at revolutionizing antibody-drug conjugate therapy for refractory breast cancers. The award, effective March 1, 2025 through February 29, 2028, will support MGH's efforts to cotarget the tumor...
The federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program totaling $1,644,309.00 supports research conducted by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to investigate functional molecular networks modifying HIF2A activity in VHL tumors. The award, effective from February 1, 2025 to January 31, 2028, will enable MGH to leverage its extensive...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), was awarded a $5,871,932 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on a scalable and efficient self-assembling vaccine platform to enable rapid development of U.S. military vaccines. The research scope includes the development of a peptide concatenation technique by the Liu-Xu Lab at Texas A&M University,...
The U.S. Defense Health Agency awarded a $888,632 project grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), under the Military Medical Research and Development (CFDA 12.420) program. The grant, titled "DECIPHERING THE ROLE OF MATERNAL AUTOANTIBODIES IN THE INDUCTION OF OFFSPRING BEHAVIORAL ABNORMALITIES FOLLOWING MATERNAL TLR7 ACTIVATION," aims to conduct advanced biomedical research focused on transforming healthcare for military...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $2,328,936 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for a 3-year research project titled "Elucidating Tumor Intrinsic and Extrinsic Drivers of Mucosal Melanoma". The grant, awarded on Sep 30, 2023, will fund MGH's biomedical research efforts to study the genetic and epigenetic landscape of mucosal melanoma,...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $730,033 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for research to develop therapies targeting AMH signaling within the ovarian cancer tumor microenvironment. The award has a performance period from April 15, 2024 to April 14, 2027. As part of its extensive biomedical research portfolio,...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program provides $819,980.00 in funding to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on elucidating sex differences in melanoma tumorigenesis. The 3-year research project, beginning on August 15, 2024 and ending on August 14, 2027, aims to advance the understanding and treatment of this complex...